Atherosclerosis of the liver allograft

Journal of Hepatology

Volumn 27, Issue 3, 1997, Pages 592-598

  McCaughan, Geoffrey W ^a   Bishop, G Alex ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT; ARTICLE; ATHEROSCLEROSIS; GRAFT REJECTION; IMMUNE RESPONSE; IMMUNOBIOLOGY; LIVER TRANSPLANTATION; PRIORITY JOURNAL;

EID: 0030775522     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80368-6     Document Type: Article

References (61)

1. Demetris AJ, Zerbe T, Banner B. Morphology of solid organ allograft arteriopathy: identification of proliferating intimal cell populations. Transplant Proc. 1:1989;3667-3669.
2. Schoen F, Libby P. Cardiac transplant graft arteriosclerosis. Trends Cardiovasc Med. 1:1991;216-223.
3. Soin AS, Rasmussen A, Jamieson NV, Watson CJE, Friend PJ, Wight DGD, et al. CsA levels in the early posttransplant period - predictive of chronic rejection in liver transplantation? Transplantation. 59:1995;1119-1123.
4. Manez R, White LT, Linden P, Kusne S, Martin M, Kramer D, et al. The influence of HLA matching on cytomegalovirus hepatitis and chronic rejection after liver transplantation. Transplantation. 55:1993;1067-1071.
5. Blatts KP, Moore SB, Perkins JD, Weisner RH, Grambsch PM, et al. Influence of positive lymphocyte crossmatch and HLA mismatch in vanishing bile duct syndrome in human liver allografts. Transplantation. 45:1988;376-379.
6. Candinas D, Gunson BK, Nightingale P, Hubscher S, McMaster P, Neuberger JM. Sex mismatch as a risk factor for chronic rejection of liver allografts. Lancet. 346:1995;1117-1121.
7. Hoffman RM, Günter C, Diepolder HM, Zachoval R, Eissner H-J, Forst H, et al. Hepatitis C virus infection as a possible risk factor for ductopenic rejection (vanishing bile duct syndrome) after liver transplantation. Transplantation. 8:1995;353-359.
8. Donaldson P, Underhill J, Doherty D, Hayllar K, Calne RY, Tan K-CJ, et al. Influence of human leukocyte antigen matching on liver allograft survival and rejection: "the dualistic effect" Hepatology. 17:1993;1008-1015.
9. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990's. Nature. 362:1993;801-809.
10. Jang Y, Lincoff AM, Plow EF, Topol EJ. Cell adhesion molecules in coronary artery disease. J Am Coll Cardiol. 24:1994;1591-1601.
11. Lefer AM. Nitric oxide: nature's naturally occurring leukocyte inhibitor. Circulation. 95:1997;553-554.
12. Bult H. Nitric oxide and atherosclerosis: possible implications for therapy. Nature Med. 1:1996;510-516.
13. Schall TJ. Biology of the Rantes/SIS cytokine family. Cytokine. 3:1991;165-183.
14. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest. 88:1991;1121-1127.
15. Jonasson J, Holm J, Skalli O, Bondjers G, Hannson GK. Regional accumulations of T cells, macrophages, and smooth muscle cells in the human atherosclerotic plaque. Arteriosclerosis. 6:1986;131-138.
16. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, et al. Expression of monocyte chemoattractant protein-1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA. 88:1991;10143-10147.
17. Jonasson L, Holm J, Skalli O, Gabbiani G, Hansson GK. Expression of class II transplantation antigens on vascular smooth muscle cells in human atherosclerosis. J Clin Invest. 76:1985;125-131.
18. Hansson GK, Jonasson L, Holm J, Claesson-Welsh L. Class II MHC antigen expression in the atherosclerotic plaque: smooth muscle cells express HLA-DR, HLA-DQ and the invariant gamma chain. Clin Exp Immunol. 64:1986;261-268.
19. Häyry P. Chronic allograft rejection: an update. Clin Transplant. 8:1994;160-161.
20. Liu G, Butany J, Wanless IR, Cameron R, Greig P, Levy G. The vascular pathology of human hepatic allografts. Hum Pathol. 24:1993;182-188.
21. Ewel CH, Foegh ML. Chronic graft rejection: accelerated transplant arteriosclerosis. Immunol Rev. 134:1993;21-31.
22. Tullius SG, Tilney NL. Both alloantigen-dependent and -independent factors influence chronic allograft rejection. Transplantation. 59:1995;313-318.
23. Libby P, Swanson SJ, Tanaka H, Murray A, Schoen F, Pober JS. Immunopathology of coronary arteriosclerosis in transplanted hearts. J Heart Lung Transplant. 11:1992;S5-S6.
24. Adams DH, Hubscher S, Fear J, Johnston J, Shaw S, Afford S. Hepatic expression of macrophage inflammatory protein-1 alpha and macrophage inflammatory protein-1 beta after liver transplantation. Transplantation. 61:1996;814-825.
25. Azuma H, Tilney NL. Chronic graft rejection. Curr Opin Immunol. 6:1994;770-776.
26. Lemström K, Koskinen P, Häyry P. Molecular mechanisms of chronic renal allograft rejection. Kidney Int. 48:1995;S2-S10.
27. Gordon D. Growth factor and cell proliferation in human transplant arteriosclerosis. J Heart Lung Transplant. 11:1992;S7.
28. Azuma H, Heemann UW, Tullius SG, Tilney NL. Cytokines and adhesion molecules in chronic rejection. Clin Transplant. 8:1994;168-180.
29. Allen MD, McDonald TO, Carlos T, Himes V, Fishbein D, Aziz S, et al. Endothelial adhesion molecules in heart transplantation. J Heart Lung Transplant. 11:1992;S8-S13.
30. Tullius SG, Heemann U, Hancock WW, Azuma H, Tilney NL. Long-term kidney isografts develop functional and morphologic changes that mimic those of chronic allograft rejection. Ann Surg. 220:1994;425-435.
31. Izutani H, Miyagawa S, Shirakura R, Matsumiya G, Nakata S, Shimazaki Y, et al. Evidence that graft coronary arteriosclerosis begins in the early phase after transplantation and progresses without chronic immunoreaction. Transplantation. 60:1995;1073-1079.
32. Maxwell SR, Moots RJ, Kendall MJ. Corticosteroids: do they damage the cardiovascular system? Postgrad Med J. 70:1994;863-870.
33. Opelz G. Influence of treatment with cyclosporine, azathioprine and steroids on chronic allograft failure. Kidney Int. 48:1995;S89-S92.
34. Tuzcu EM, De Franco AC, Goormastic M, Hobbs RE, Rincon G, Bott-Silverman C, et al. Dichotomous pattern of coronary atherosclerosis 1 to 9 years after transplantation: insights from systematic intravascular ultrasound imaging. J Am Coll Cardiol. 27:1996;839-846.
35. Anderson ND, Wyllie RG, Shaker IJ. Pathogenesis of vascular injury in rejecting rat renal allografts. John Hopkins Med J. 141:1977;135-147.
36. Dvorak HF, Mihm MC, Dvorak AM, Barnes BA, Manseou EJ, Galli SJ. Rejection of first set skin allografts in man: the microvasculature is the critical target of the immune response. J Exp Med. 150:1979;322-337.
37. Hengstenberg C, Rose ML, Page C, Taylor PT, Yacoub MH. Immunocytochemical changes suggestive of damage to endothelial cells during rejection of human cardiac allografts. Transplantation. 49:1990;895-899.
38. Matsumoto Y, McCaughan GW, Painter DM, Bishop GA. Evidence that portal tract microvascular destruction precedes bile duct loss in human liver allograft rejection. Transplantation. 56:1993;69-75.
39. Oguma S, Belle S, Starzl T, Demetris AJ. A histometric analysis of chronically rejected human liver allografts: insights into the mechanisms of bile duct loss: direct immunologic and ischaemic factors. Hepatology. 9:1989;204-209.
40. Lawrence MB, Springer TA. Leukocytes roll on a selectin at physiologic flow rates: distinction from and prerequisite for adhesion through integrins. Cell. 65:1991;859-873.
41. Sun J, Williams J, Yan HC, Amin KM, Albelda SM, De Lisser HM. Platelet endothelial cell adhesion molecule-1 (PECAM-1) homophilic adhesion is mediated by immunoglobulin-like domains 1 and 2 and depends on the cytoplasmic domain and the level of surface expression. J Biol Chem. 271:1996;18561-18570.
42. McNab G, Reeves JL, Salmi M, Hubscher S, Jalkanen S, Adams DH. Vascular adhesion protein-1 mediates binding of T cells to human hepatic endothelium. Gastroenterology. 110:1996;522-528.
43. Deligeorgi-Politi H, White DGD, Calne RY. Chronic rejection of liver transplants revisited. Transplant Int. 7:1994;442-447.
44. McCaughan GW, Davies S, Waugh J, Bishop GA, Hall B, Gallagher ND, et al. A quantitative analysis of T Iymphocyte populations in human liver allografts undergoing rejection: the use of monoclonal antibodies and double immunolabelling. Hepatology. 12:1990;1305-1313.
45. Ludwig J, Batts KP, Ploch M, Rakela J, Perkins JD, Weisner RH. Endotheliitis in hepatic allografts. Mayo Clin Proc. 64:1989;545-554.
46. Xiao F, Chong A, Shen J, Yang J, Short J, Foster P, et al. Pharmacologically induced regression of chronic transplant rejection. Transplantation. 60:1995;1065-1072.
47. Azuma H, Binder J, Heeman U, Schmid C, Tullius SG, Tilney NL. Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation. 59:1995;460-466.
48. Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet. 344:1994;423-428.
49. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med. 331:1994;1110-1115.
50. Adams DH, Russell ME, Hancock WW, Sayegh MH, Wyner LR, Karnovsky MJ. Chronic rejection in experimental cardiac transplantation: studies in the Lewis-F344 model. Immunol Rev. 134:1993;4-19.
51. Foegh ML, Ramwell PW. Angiopeptin: experimental and clinical studies of inhibition of myointimal proliferation. Kidney Int. 48:1995;S18-S22.
52. Häyry P, Isoniemi H, Yilmaz S, Mennander A, Lemström K, Räisänen-Sokolowski A, et al. Chronic allograft rejection. Immunol Rev. 134:1993;33-81.
53. Heldin CH, Westermark B. Possible in vivo effect and clinical utility of platelet-derived growth factor and PDGF antagonist. Transplant Proc. 25:1993;2074-2076.
54. Adams MR, Jessup W, Hailstones D, Celermajer DS. L-Arginine reduces human monocyte adhesion to vascular endothelium and endothelial expression of cell adhesion molecules. Circulation. 95:1997;662-668.
55. Campbell GR, Campbell JH. Smooth muscle diversity: implications for the question: what is a smooth muscle cell? Biomed Res. 1997;. in press.
56. Demetris AJ, Markus BH. Immunopathology of liver transplantation. Crit Rev Immunol. 9:1989;67-92.
57. Adams DH, Shaw J, Hubscher SG, Rothlein R, Neuberger JM. Intercellular adhesion molecule 1 on liver allografts during rejection. Lancet. i:1989;1122-1125.
58. Bloom S, Fleming K, Chapman R. Adhesion molecule expression in primary sclerosing cholangitis and primary biliary cirrhosis. Gut. 36:1995;604-605.
59. Garcia-Barcina M, Lukomska B, Gawron W, Winnock M, Vidal-Vanaclocha F, Bioulac-Sage P, et al. Expression of cell adhesion molecules on liver-associated lymphocytes and their ligands on sinusoidal lining cells in patients with benign or malignant liver disease. Am J Pathol. 146:1995;1406-1413.
60. Steinhoff G, Behrend M, Schrader B, Duijvestijn AM, Wonigeit K. Expression patterns of leukocyte adhesion ligand molecules on human liver endothelia. Am J Pathol. 142:1993;481-488.
61. Yasoshima M, Nakanuma Y, Tsuneyama K, Van de Water J, Gershwin ME. Immunohistochemical analysis of adhesion molecules in the micro-environment of portal tracts in relation to aberrant expression of PDC-E2 and HLA-DR on the bile ducts in primary biliary cirrhosis. J Pathol. 175:1995;319-325.